Generate Biomedicines, Inc. (GENB) stock
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)
Close on Nov 17, 2026Market cap $1.26BP/E –Yield –
Generate Biomedicines cash
Cash and short-term investments held at the end of each period.
Generate Biomedicines's cash was $404.20M at Sep 30, 2026. For fiscal 2025 it was $221.50M.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $221.50M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $404.20M | +241.0% |
| Q2 FY2026 | Jun 30, 2026 | $457.40M | +196.5% |
| Q1 FY2026 | Mar 31, 2026 | $516.60M | +134.2% |
| Q4 FY2025 | Dec 31, 2025 | $221.50M | – |
| Q3 FY2025 | Sep 30, 2025 | $118.52M | – |
| Q2 FY2025 | Jun 30, 2025 | $154.27M | – |
| Q1 FY2025 | Mar 31, 2025 | $220.61M | – |
See a number that looks wrong?